In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase

Gene Therapy

Volumn 8, Issue 20, 2001, Pages 1547-1554

  Chung Faye, G A ^a   Chen, M J ^a   Green, N K ^a   Burton, A ^a   Anderson, D ^a   Mautner, V ^a   Searle, P F ^a   Kerr, D J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

5 fluorocytosine; 5 fluorouracil; Adenovirus; Colon cancer; Uracil phosphoribosyl transferase; VDEPT

Indexed keywords

CYTOSINE DEAMINASE; DRUG METABOLITE; FLUCYTOSINE; FLUOROURACIL; PRODRUG; URACIL PHOSPHORIBOSYLTRANSFERASE;

ADENOVIRUS; ANIMAL CELL; ARTICLE; CANCER CELL; COLON CANCER; CONTROLLED STUDY; DNA SYNTHESIS; FUSION GENE; GENE CONVERSION; GENE THERAPY; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SYNTHESIS; SENSITIZATION; TUMOR GROWTH; VIRUS REPLICATION; XENOGRAFT;

ADENOVIRIDAE; ANALYSIS OF VARIANCE; ANIMALS; ARTIFICIAL GENE FUSION; BYSTANDER EFFECT; COLONIC NEOPLASMS; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; GENE THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRALESIONAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NUCLEOSIDE DEAMINASES; PENTOSYLTRANSFERASES; PRODRUGS; RANDOM ALLOCATION; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0035158045     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301557     Document Type: Article

References (16)

1. Surgical treatment of liver metastases in patients with colorectal cancer
2. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
3. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system
4. A first step in the development of gene therapy for colorectal carcinoma: Cloning, sequencing, and expression of Escherichia coli cytosine deaminase
5. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine
6. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral pro-drug 5-fluorocytosine
7. Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine
8. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil
9. Tumor-specific gene expression in carcinoembryonic antigen-producing gastric cancer cells using adenovirus vectors
10. Recommended 5-fluorocytosine dose in patients
11. Cytosine deaminase/5-fluorocytosine-based vaccination against liver tumors: Evidence of distant bystander effect
12. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
13. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene
14. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector
15. Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors
16. Random-effects models for longitudinal data